Compass Therapeutics Inc. Total Assets
Compass Therapeutics Inc. total assets. Based on the latest financial reports, Compass Therapeutics Inc. (CMPX) holds total assets worth $190.17 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see CMPX cash generation efficiency for how efficiently the company converts equity into cash flow.
Total Assets of Compass Therapeutics Inc. (2018–2025)
Total assets of Compass Therapeutics Inc. from 2018 to 2025. This chart illustrates how Compass Therapeutics Inc.'s total assets have evolved over time, based on quarterly financial data. See Compass Therapeutics Inc. stock price for real-time trading data and today's change.
Compass Therapeutics Inc. - Asset Composition Analysis
Compass Therapeutics Inc. Total Assets Breakdown (December 2025)
Compass Therapeutics Inc. total assets breakdown as of December 2025. Compass Therapeutics Inc.'s total assets of $190.17 Million consist of 95.6% current assets and 4.5% non-current assets. Explore Compass Therapeutics Inc. working capital to net assets to assess how much short-term liquidity the company maintains relative to its equity base.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 14.0% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2025)
This chart illustrates how Compass Therapeutics Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Compass Therapeutics Inc.'s current assets represent 95.6% of total assets in 2025, an increase from 91.1% in 2018.
- Cash Position: Cash and equivalents constituted 14.0% of total assets in 2025, down from 89.0% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Compass Therapeutics Inc. Competitors by Total Assets
Key competitors of Compass Therapeutics Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Braveheart Bio, Inc. Common Stock
NASDAQ:BRVE
|
USA | $126.96 Million |
|
PHARVARIS N.V. EO -12
F:9EN
|
Germany | €301.45 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488
|
China | CN¥1.98 Billion |
Compass Therapeutics Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 11.22 | 7.66 | 3.72 |
| Quick Ratio | 11.22 | 7.66 | 3.72 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $164.76 Million | $92.34 Million | $20.89 Million |
Compass Therapeutics Inc. - Advanced Valuation Insights
This section examines the relationship between Compass Therapeutics Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.27 |
| Latest Market Cap to Assets Ratio | 0.62 |
| Asset Growth Rate (YoY) | 56.4% |
| Total Assets | $219.59 Million |
| Market Capitalization | $136.18 Million USD |
Valuation Analysis
Below Book Valuation: The market values Compass Therapeutics Inc.'s assets below their book value (0.62x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Compass Therapeutics Inc.'s assets grew by 56.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Compass Therapeutics Inc. (2018–2025)
The table below shows the annual total assets of Compass Therapeutics Inc. from 2018 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $219.59 Million | +56.40% |
| 2024-12-31 | $140.40 Million | -10.50% |
| 2023-12-31 | $156.88 Million | -21.42% |
| 2022-12-31 | $199.65 Million | +29.84% |
| 2021-12-31 | $153.76 Million | +196.19% |
| 2020-12-31 | $51.91 Million | +70.87% |
| 2019-12-31 | $30.38 Million | -52.99% |
| 2018-12-31 | $64.62 Million | -- |
About Compass Therapeutics Inc.
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tum… Read more